Name: Latest research reports of Eris Lifesciences Ltd. authored by Prabhudas Lilladhar and published by - Trendlyne research reports.
Item: Eris Lifesciences Ltd.
Rating: 5
Author: Prabhudas Lilladhar

Summary	Date	Stock	Author	LTP	Target	Price at reco (Change since reco%)	Upside(%)	Type	Report	Discuss
	16 Sep 2025	Eris Lifesciences	Consensus Share Price Target	1662.00	1860.10	-	11.92	buy	pdf Detailed Estimates
	25 Oct 2022	Eris Lifesciences	Prabhudas Lilladhar Target	1662.00	850.00	726.75 (128.69%)	Target met	Buy	pdf post cache	Broker Report ERIS LIFESCIENCES LT Prabhudas Lilladhar pdf Copy Link Share on Share on Share on Share on Alert
	08 Aug 2022	Eris Lifesciences	Prabhudas Lilladhar Target	1662.00	825.00	696.30 (138.69%)	Target met	Buy	pdf post cache	Broker Report ERIS LIFESCIENCES LT Prabhudas Lilladhar pdf Copy Link Share on Share on Share on Share on Alert
	16 May 2022	Eris Lifesciences	Motilal Oswal	1662.00	870.00	698.30 (138.01%)		Buy	pdf post cache	Broker Report Niche launches to aid growth over the medium term Motilal Oswal pdf Copy Link Share on Share on Share on Share on Alert
	05 May 2022	Eris Lifesciences	Prabhudas Lilladhar Target	1662.00	850.00	672.15 (147.27%)		Buy	pdf post cache	Broker Report ERIS LIFESCIENCES LT Prabhudas Lilladhar pdf Copy Link Share on Share on Share on Share on Alert
	05 May 2022	Eris Lifesciences	Motilal Oswal	1662.00	870.00	670.10 (148.02%)		Buy	pdf post cache	Broker Report In line 4QFY22 at the operational level; geared up for launches in FY23 Motilal Oswal pdf Copy Link Share on Share on Share on Share on Alert
	29 Jan 2022	Eris Lifesciences	BOB Capital Markets Ltd. Target	1662.00	890.00	698.50 (137.94%)		Buy	pdf post cache	Broker Report Eris Lifesciences (BUY): Cardio-metabolic segment headwinds hamper growth BOB Capital Markets Ltd. Industry-wide slowdown in cardiometabolic segment (59% revenue share for ERIS) affected Q3 growth pdf Copy Link Share on Share on Share on Share on Alert
	27 Dec 2021	Eris Lifesciences	Motilal Oswal	1662.00	870.00	732.45 (126.91%)		Buy	pdf post cache	Broker Report Mix of Chronic portfolio, rising coverage, and better operating leverage to drive earnings growth Motilal Oswal pdf Copy Link Share on Share on Share on Share on Alert
	07 Dec 2021	Eris Lifesciences	BOB Capital Markets Ltd.	1662.00	975.00	723.20 (129.81%)		Buy	pdf post cache	Broker Report First Light \| Eris Lifesciences BOB Capital Markets Ltd. ERIS: Foray into India's insulin market pdf Copy Link Share on Share on Share on Share on Alert
	06 Dec 2021	Eris Lifesciences	Prabhudas Lilladhar	1662.00	954.00	729.65 (127.78%)		Buy	pdf post cache	Broker Report Event Update - JV with M.J.Biopharm Ltd. to widen offerings in diabetics market - BUY Prabhudas Lilladhar our positive stance on ERIS given 1) scheduled potential launches, 2) strong pipeline of patent expiration opportunities and 3) rapidly growing new-generation brands along with power brands in core therapies. ERIS's timely strategy of capacity expansion and higher contribution from chronic/sub-chronic products supported by insignificant regulatory risk, allows it to stand ahead in the industry. We have not factored any revenues and expenses from this JV. Maintain our BUY'... pdf Copy Link Share on Share on Share on Share on Alert
	06 Dec 2021	Eris Lifesciences	BOB Capital Markets Ltd. Reco Target	1662.00	975.00	698.15 (138.06%)		Buy	pdf post cache	Broker Report Eris Lifesciences (BUY): Foray into India's insulin market BOB Capital Markets Ltd. ERIS enters ten-year, 70:30 JV with MJ Biopharm for marketing rh-insulin, insulin analogues, GLP1 agonists and biosimilars pdf Copy Link Share on Share on Share on Share on Alert
more loading

51.48% Gain from 52W Low

Eris Lifesciences Ltd. share price target

Eris Lifesciences Ltd. has an average share price target of 1581. The consensus estimate represents a downside of -4.87% from the last price of 1662. View 7 reports from 3 analysts offering long-term price targets for Eris Lifesciences Ltd..

ERIS LIFESCIENCES LT

ERIS LIFESCIENCES LT

Niche launches to aid growth over the medium term

ERIS LIFESCIENCES LT

In line 4QFY22 at the operational level; geared up for launches in FY23

Eris Lifesciences (BUY): Cardio-metabolic segment headwinds hamper growth

Mix of Chronic portfolio, rising coverage, and better operating leverage to drive earnings growth

First Light | Eris Lifesciences

Event Update - JV with M.J.Biopharm Ltd. to widen offerings in diabetics market - BUY

Eris Lifesciences (BUY): Foray into India's insulin market

Advisor Screeners